Twenty-two patients with CD4(+)cell counts <or=200 cells/microL after 12 months of stable highly active antiretroviral therapy (HAART; "immunologic nonresponders") were randomly assigned to receive subcutaneous low-dose prolonged intermittent interleukin (IL)-2 in addition to HAART (n=12) or to continue HAART alone (n=10). At 48 weeks of follow-up, no IL-2-related serious adverse events and no significant differences in plasma human immunodeficiency virus (HIV) RNA level were observed in the 2 groups. A higher incidence of HIV-related clinical events was observed among patients receiving HAART alone (3/10) than among subjects receiving HAART plus IL-2 (0/12). Significant increases in CD4(+), naive, and CD4(+)CD7(+) cells and plasma levels of IL-7 were observed in patients receiving IL-2 versus patients receiving HAART alone. A significant increase in cell turnover did not lead to a decrease in the frequency of T cell receptor excision circles, which remained stable. Rather, increased numbers of T cell receptor excision circles per microliter of blood were observed (not statistically significant). Thus, adjuvant IL-2 therapy in immunologic nonresponders resulted in a clinical benefit, suggesting that the quantitative cell recovery involves functionally competent immune cells.
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment / G. Marchetti, L. Meroni, S. Varchetta, V. Terzieva, A. Bandera, D. Manganaro, C. Molteni, D. Trabattoni, S. Fossati, M. Clerici, M. Galli, M. Moroni, F. Franzetti, A. Gori. - In: THE JOURNAL OF INFECTIOUS DISEASES. - ISSN 0022-1899. - 186:5(2002), pp. 606-616. ((Intervento presentato al 8. convegno Conference on Retroviruses and Opportunistic Infections tenutosi a Chicago nel 2001.
|Titolo:||Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment|
MARCHETTI, GIULIA CARLA (Corresponding)
|Parole Chiave:||active antiretroviral therapy; HIV-infected patients; recent thymic emigrants; pneumocystis-carinii pneumonia; Pineral hormone melatonin; T-cell homeostasis; subcutaneous interleukin-2; phase-II; lymphocyte apoptosis; primary prophylaxis|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
Settore MED/04 - Patologia Generale
|Data di pubblicazione:||2002|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1086/342479|
|Appare nelle tipologie:||01 - Articolo su periodico|